Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary) ; Hib vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine (Primary) ; Measles mumps and rubella virus vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Rotavirus W179-9 vaccine (Primary) ; V 114 (Primary) ; Varicella zoster virus vaccine live (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms PNEU-DIRECTION
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 29 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 17 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top